Trial Profile
A PHASE 2, OPEN LABEL, MULTI-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Pamufetinib (Primary) ; Abiraterone acetate; Docetaxel
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 16 Feb 2019 Results (n=50) evaluating the efficacy and safety of TAS-115 in castration resistant prostate cancer patients with bone metastases presented at the 2019 Genitourinary Cancers Symposium
- 03 Aug 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 03 Aug 2018 Status changed from recruiting to active, no longer recruiting.